ADAM metallopeptidase with thrombospondin type 1 motif 18Genealiases: ADAMTS21 · KNO2 · MMCAT
Q-omics provides the consensus-scored ADAMTS18 profile across patient tissues and cancer cell-line models. ADAMTS18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ADAMTS18 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ADAMTS18 RNA expression shows 15,955 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, THCA, and TGCT as cancer lineages where ADAMTS18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS18 survival associations across molecular data types. ADAMTS18 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS18 RNA expression–survival associations across cancer types. High ADAMTS18 expression shows unfavorable associations in BLCA, UVM, STAD, LGG and KIRP, but favorable associations in HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ADAMTS18 RNA expression.
This table summarizes ADAMTS18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ADAMTS18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS18 shows lower tumor expression in BRCA and higher tumor expression in THCA, UCEC, KIRC, LUAD and STAD. The THCA box plot shows higher ADAMTS18 RNA expression in tumor versus normal tissue (log2 FC = +0.632, t-test p < 0.001).
This table shows molecular features associated with ADAMTS18 in patient tissues and cancer cell lines. In patient samples, ADAMTS18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
